Topical triamcinolone acetonide vs pimecrolimus 1%: Adverse effects
- Population
- People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
- Intervention
- Topical triamcinolone acetonide
- Comparison
- pimecrolimus 1%
- Outcome
- Adverse effects
Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topical triamcinolone acetonide vs Topical pimecrolimus Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment · end of treatment Topical triamcinolone acetonide showed no clear difference in adverse effects compared with topical pimecrolimus; GRADE not reported. Interventions for treating oral lichen planus: corticosteroid therapies (2020) · Cochrane All outcomes | RR 0.21 [0.01, 4.10] | 1 study · 35 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes | 2019-02 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Topical triamcinolone acetonide vs Topical tacrolimus · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently… · 1 review
- Topical triamcinolone acetonide vs Topical ciclosporin · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently… · 1 review
- Topical triamcinolone acetonide vs Intralesional BCG-polysaccharide nucleic acid (BCG-PSN) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently… · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.